Impact of Concomitant Surgical Procedures in a Randomized Controlled Trial of Aspirin Removal in Left Ventricular Assist Device Patients - An Analysis from The ARIES Trial

Purpose: ARIES is an international, placebo-controlled, study of aspirin (100mg daily) in patients implanted with the HM3 LVAD to demonstrate that elimination of aspirin from the antithrombotic regimen preserves safety and efficacy and reduces residual risk of non-surgical bleeding complications. The primary endpoint results of the ARIES HM3 Trial will be presented in November 2023. In this analysis, we seek to analyze the impact of concomitant procedures (stratified by valvular and non-valvular surgery) on hemocompatibility related outcomes within the study.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research